Drummand M, Members of the ISPOR HTA Council Working Group on HTA in Pluralistic Healthcare Systems, Ronquest N. A case of multitasking: conducting and using HTA and HEOR in pluralistic healthcare systems. Value & outcomes spotlight. 2022 Jul;8(4):7-9.
Wardman M, Chintakayala P, Heywood C. The valuation and demand impacts of the worthwhile use of travel time with specific reference to the digital revolution and endogeneity. Transportation. 2019 Oct 23;47:1515-40. doi: 10.1007/s11116-019-10059-x
Batley R, Bates J, Bliemer M, Borjesson M, Bourdon J, Cabral MO, Chintakayala P, Choudhury C, Daly A, Dekker T, Drivyla E, Fowkes T, Hess S, Heywood C, Johnson D, Laird J, Mackie P, Parkin J, Sanders S, Sheldon R, Wardman M, Worsley T. New appraisal values of travel time saving and reliability in Great Britain. Transportation. 2019 Jun;46:583-621. doi: 10.1007/s11116-017-9798-7
Wolowacz SE. Task force recommendations on the collection of health-state utility data in clinical studies: an interview with Sorrel E. Wolowacz, PhD, Co-Chair, on good practices for Outcomes Research Task Force. Value & outcomes spotlight. 2016 Sep;2(5):22-3.
Bristow AL, Wardman M, Chintakayala VPK. International meta-analysis of stated preference studies of transportation noise nuisance. Transportation. 2015;42:71-100. doi: 10.1007/s11116-014-9527-4
Shakoor A, Esterberg E, Acharya NR. Recurrence of uveitis after discontinuation of infliximab. Ocul Immunol Inflamm. 2014 Apr;22(2):96-101. doi: 10.3109/09273948.2013.812222
Martel JN, Esterberg E, Nagpal A, Acharya NR. Infliximab and adalimumab for uveitis. Ocul Immunol Inflamm. 2012 Feb;20(1):18-26. doi: 10.3109/09273948.2011.633205.